AYTU BIOPHARMA, INC

AYTU BIOPHARMA, INC is a pharmaceutical company that develops innovative medicines for complex central nervous system diseases. The company was originally incorporated as Rosewind Corporation on August 9, 2002, in Colorado, and re-incorporated as Aytu BioScience, Inc. in Delaware on June 8, 2015. In March 2021, the company changed its name to Aytu BioPharma, Inc. Its common stock trades on the Nasdaq Capital Market LLC under the ticker symbol "AYTU." AYTU BIOPHARMA, INC focuses on in-licensing, acquiring, developing, and commercializing novel prescription therapeutics to build its portfolio of revenue-generating products. In June 2025, the company entered into an Exclusive Commercialization Agreement with Fabre-Kramer Holdings, Inc. to commercialize EXXUA (Gepirone) extended-release tablets in the United States. EXXUA is a new chemical entity and a selective serotonin 5HT1a receptor agonist approved by the United States Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults. In fiscal 2026, AYTU BIOPHARMA, INC began selling EXXUA, making it the primary focus of its commercial efforts. EXXUA has been studied in over 5,000 patients and competes in the United States prescription MDD market, which was valued at over $22 billion. The company aims to provide a new treatment option for the estimated 21.0 million Americans affected by MDD. In 2025, over 360 million antidepressant prescriptions were written in the United States.